Otenzepad

Otenzepad
	Structure of Otenzepad
Clinical data
Routes of; administration	oral
Pharmacokinetic data
Bioavailability	45% (oral)
Elimination half-life	2.5h
Identifiers
	IUPAC name 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;
CAS Number	102394-31-0 ;
PubChem CID	107867;
IUPHAR/BPS	309;
ChemSpider	97004;
UNII	OM7J0XAL0S;
ChEBI	CHEBI:111174;
ChEMBL	ChEMBL17045;
CompTox Dashboard (EPA)	DTXSID0045674 ;
ECHA InfoCard	100.220.541
Chemical and physical data
Formula	C24H31N5O2
Molar mass	421.545 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4;
	InChI InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31); Key:UBRKDAVQCKZSPO-UHFFFAOYSA-N;

Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.^[1]

Pharmacodynamics

The (+)-enantiomer has 8 times greater potency at the M2 receptor than the (-)-enantiomer.^[1]

^ ^a ^b ^c ^d ^e ^f ^g ^h "Otenzepad". National Centre for Advancing Translational Sciences. Retrieved 10 June 2021.
^ ^a ^b ^c ^d ^e Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989). "Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells". Mol. Pharmacol. 35 (4): 469–76. PMID 2704370.